Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Company Overview

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $19.44 to $20.67
• 50-Day Range: $18.08 to $25.48
• 52-Week Range: $17.52 to $45.00
• Volume: 387,447 shs
• Average Volume: 478,549 shs
• Market Capitalization: $554.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $71.40
• Consensus Rating: Buy

Arcturus Therapeutics Stock Analysis - MarketRank™

Arcturus Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 383rd out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Arcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Arcturus Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.60) to $0.20 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcturus Therapeutics is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcturus Therapeutics is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcturus Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.62% of the float of Arcturus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcturus Therapeutics has recently decreased by 12.05%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Arcturus Therapeutics does not currently pay a dividend.

Dividend Growth

Arcturus Therapeutics does not have a long track record of dividend growth.

Dividend Sustainability

Based on EPS estimates, Arcturus Therapeutics will have a dividend payout ratio of 357.50% in the coming year. This indicates that Arcturus Therapeutics may not be able to sustain their current dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.62% of the float of Arcturus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcturus Therapeutics has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Arcturus Therapeutics has recently decreased by 12.05%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.03

News Sentiment

Arcturus Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.

MarketBeat Follows

5 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $249,120.00 in company stock.

Percentage Held by Insiders

13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARCT Stock Analysis - Frequently Asked Questions

How have ARCT shares performed this year?

Arcturus Therapeutics' stock was trading at $31.53 at the beginning of the year. Since then, ARCT shares have decreased by 34.7% and is now trading at $20.60.
View the best growth stocks for 2024 here.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings results on Monday, August, 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($1.85) by $1.21. The biotechnology company had revenue of $49.86 million for the quarter, compared to the consensus estimate of $21 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 25.47% and a negative net margin of 41.21%.

Who are Arcturus Therapeutics' major shareholders?

Top institutional investors of Arcturus Therapeutics include Vontobel Holding Ltd. (0.11%), SG Americas Securities LLC (0.03%) and nVerses Capital LLC (0.01%). Insiders that own company stock include Pad Chivukula, Magda Marquet and Keith C Kummerfeld.
View institutional ownership trends.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/05/2024
• Today: 10/17/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARCT
• CUSIP: N/A
• CIK: 1410997
• Web: www.arcturusrx.com
• Phone: (858) 900-2660
• Fax: N/A
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $71.40
• High Stock Price Target: $90.00
• Low Stock Price Target: $48.00
• Potential Upside/Downside: +246.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,730,000.00
• Net Margins: -41.21%
• Pretax Margin: -42.27%
• Return on Equity: -25.47%
• Return on Assets: -16.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.78
• Quick Ratio: 3.78

Sales & Book Value

• Annual Sales: $147.03 million
• Price / Sales: 3.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.42 per share
• Price / Book: 1.98

Miscellaneous

• Outstanding Shares: 26,932,000
• Free Float: 22,811,000
• Market Cap: $554.80 million
• Optionable: Optionable
• Beta: 2.61